Analyst Consensus ?
ConsensusHold28 ratings
Bullish828.6%
Neutral1657.1%
Bearish414.3%
GSK plc · GSK · FY2026 Q2 · Calendar Q3 2026
Gibson Energy sustains infrastructure growth while managing leverage
The supplied analysis supports a constructive operating thesis: infrastructure demand, connectivity projects and strong refined-product margins are supporting growth, while leverage and execution remain the key tests.
Reported Before market openNYSEHealthcare
$99.24B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.36
Consensus $1.27
EPS surprise
+7.1%
Reported versus consensus
Reported revenue
$11.18B
Consensus $11.02B
Revenue surprise
+1.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+3.3%
Event window
SPY move
+0.2%
Same window
Abnormal move
+3.1%
Stock minus SPY
Volume
2.0×
Versus trailing sessions
Subsequent drift
-3.1%
Up to 20 sessions
GSKSPY benchmark
Ask FN2 about GSK FY2026 Q2
Transcript, numbers and history already loaded
Why did GSK rise 3.3% after beating EPS estimates in FY2026 Q2?What changed in GSK's guidance and outlook in FY2026 Q2?Give me the bull and bear case for GSK after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Infrastructure adjusted EBITDA reached a record CAD 169 million, the Chauvin Pipeline acquisition closed, and management advanced expansion and integration projects. Financing capacity was extended and senior notes were issued.
Guidance delta
Maintained; management reported no change to its allocation priorities.
Key takeaways
- Infrastructure adjusted EBITDA was a record CAD 169 million, up CAD 17 million year over year.
- The Chauvin acquisition and planned capacity expansion remain on track for a year-end final investment decision.
- Management highlighted strong crack spreads, additional connectivity and producer demand as growth drivers.
- Balance-sheet flexibility remains a focus, with leverage targeted at 3–3.5x by early 2027.
Management priorities
- Complete the Hardisty connection project.
- Advance the Chauvin expansion and target final investment decision by year-end.
- Finalize Wink-to-Gateway integration and pipeline-twinning work.
- Evaluate additional tankage while pursuing selective bolt-on acquisitions.
Follow GSK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$49.51Current
$35.25Low
$48.86Average
$60High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Jefferies | Hold | Buy | Downgrade | Oct 29, 2026 |
| Barclays | Underweight | Equal Weight | Downgrade | Jan 6, 2026 |
| Guggenheim | Neutral | Buy | Downgrade | Oct 31, 2024 |
| UBS | Neutral | Buy | Downgrade | Jul 8, 2024 |
| DZ Bank | Hold | Buy | Downgrade | Feb 11, 2022 |
| SVB Leerink | Market Perform | Outperform | Downgrade | Mar 23, 2021 |
| Deutsche Bank | Sell | Hold | Downgrade | Feb 4, 2021 |
| Argus Research | Buy | Buy | Maintain | Nov 11, 2019 |
| New Street | Hold | Reduce | Upgrade | Oct 16, 2019 |
| Cantor Fitzgerald | Buy | Hold | Upgrade | Oct 11, 2019 |
| Societe Generale | Buy | Sell | Upgrade | Sep 3, 2019 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Jan 14, 2019 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Dec 14, 2018 |
| Morgan Stanley | Underweight | Underweight | Maintain | Dec 14, 2018 |
| Argus | Buy | Buy | Maintain | Aug 20, 2018 |
| Bank of America | Neutral | Buy | Downgrade | Oct 26, 2017 |
| Citigroup | Neutral | Buy | Downgrade | Jul 5, 2017 |
| PiperJaffray | Overweight | Overweight | Maintain | Sep 23, 2016 |
| Bryan Garnier | Buy | Neutral | Upgrade | Jan 27, 2016 |
| Credit Suisse | Neutral | Underperform | Upgrade | Oct 20, 2015 |
| JP Morgan | Neutral | Underweight | Upgrade | Oct 12, 2015 |
| Mainfirst | Underperform | Underperform | Maintain | Jul 28, 2014 |
| Panmure | Buy | Hold | Upgrade | Apr 22, 2014 |
| S&P Capital IQ | Hold | Sell | Upgrade | Jan 27, 2014 |
| Berenberg | Hold | Buy | Downgrade | Jan 24, 2014 |
| Cowen & Co. | Market Perform | Outperform | Downgrade | Jan 22, 2014 |
| Liberum | Hold | Underweight | Upgrade | Jun 7, 2013 |
| Kepler Cheuvreux | Buy | Hold | Upgrade | Feb 8, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $49.51. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Jefferies | Analyst unavailable | $55.9 | $48.74 | +12.9% | Oct 29, 2026 |
| Berenberg Bank | Kerry Holford | $60 | $50.05 | +21.2% | Sep 15, 2026 |
| CFRA | Wan Nurhayati | $53 | $46.67 | +7.0% | Oct 30, 2025 |
| BNP Paribas | Peter Verdult | $35.25 | $35.68 | -28.8% | Apr 15, 2025 |
| Jefferies | Peter Welford | $53 | $38.38 | +7.0% | Jul 2, 2024 |
| Guggenheim | Vamil Divan | $36 | $40.69 | -27.3% | Apr 11, 2024 |
Track every rating change on GSK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio.…
Historical context
All GSK earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the GSK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-28T18:04:44.376900+00:00
- FN2 earnings calendar · 2026-09-02T01:23:14.593608+00:00
- Polygon adjusted daily market bars · 2026-10-31T19:20:43.826240+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T19:20:43.823370+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.